Differential expression of melanoma-associated antigens and molecules involved in antigen processing and presentation in three cell lines established from a single patient

Melanoma Research

Volumn 14, Issue 6, 2004, Pages 463-471

  Kovalcsik, Edit ^a   John, Justin ^a   Turner, Matthew ^a   Birchall, Lindsay ^a   Sage, Deborah ^b   Whittle, Robert ^b   Dalgleish, Angus ^a   Pandha, Hardev ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

Antigen processing transporters; Flow cytometry; Human leukocyte antigen; Interferon ; Melanoma associated antigen; Metastatic melanoma; Reverse transcription polymerase chain reaction; Western blot

Indexed keywords

BETA ACTIN; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA B38 ANTIGEN; HLA B7 ANTIGEN; LOW MOLECULAR WEIGHT PROTEIN 2; MELAN A; MELANOMA ANTIGEN 1; MONOPHENOL MONOOXYGENASE; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BRAIN METASTASIS; CANCER CELL CULTURE; CEREBELLUM; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MELANOMA; METASTASIS; PARIETAL LOBE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGY; SKIN METASTASIS; TUMOR CELL; WESTERN BLOTTING;

ANTIGEN PRESENTATION; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN NEOPLASMS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-B ANTIGENS; HLA-B7 ANTIGEN; HUMANS; INTERFERON TYPE II; LYMPHOCYTES; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 13544263523     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200412000-00005     Document Type: Article

References (28)

1. Bouvier M. Accessory proteins and the assembly of human class I MHC molecules: a molecular and structural perspective. Mol Immunol 2003; 39(12):697-796.
2. Singal DP, Ye M, Quadri SA. Major histocompatibility-encoded human proteasome LMP2. JBC Online 1995; 270(4):1966-1970.
3. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumour growth. Immunol Today 2000; 21(9):455-464.
4. Thor Straten P, Kirkin AF, Seremet T, Zeuthen J. Expression of transporters associated with antigen processing 1 and 2 (TAP 1/2) in malignant melanoma cell lines. Int J Cancer 1997; 70:582-586.
5. Kawakami Y, Battles JIK, Kobayashi T, Ennis W, Wang X, Tupesis JP, et al. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J Immunol Methods 1997; 202:13-25.
6. Seliger B, Maeurer MJ, Ferrone S. TAP off - tumours on. Immunol Today 1997; 18(6):292-299.
7. Saleh FH, Crotty KA, Hersey P, Menzies SW. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen Melan-A/MART-1. Int J Cancer 2001; 94:551-557.
8. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003; 195: 346-355.
9. Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, Restifo NP. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol 2000; 164:3535-3542.
10. Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L, Kalbacher H. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 1997; 57(15):3238-3244.
11. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998; 75:517-524.
12. Le Poole IC, Riker AI, Quevedo ME, Stennett LS, Wang E, Marincola FM, et al. Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol 2002; 160(21):521-528.
13. Paschen A, Mendez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, et al. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 2002; 103:759-767.
14. Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, et al. Low-dose IFN-γ induces tumor MHC expression in metastatic maliagnant melanoma. Clin Cancer Res 2003; 9:84-92.
15. Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutler G, et al. Immune escape of melanoma. Cancer Res 2001 ; 61:8647-8650.
16. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18(2):89-95.
17. Ruiz-Cabello F, Garrido F. HLA and cancer: from research to clinical impact. Immunol Today 1998; 19(12):539-542.
18. Matsui M, Machida S, Itani-Yohda T, Akatsuka T. Treatment of hepatocellular carcinoma. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-γ. J Gastroenterol Hepatol 2002; 17:897-907.
19. Seliger B, Hammers S, Hohne A, Zeidler R, Knuth A, Gerharz CD, Huber C. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin Cancer Res 1997; 4:573-578.
20. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma. Am J Pathol 1999; 154:745-754.
21. Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, et al. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumour cell recognition by cytotoxic T lymphocytes. Int J Cancer 2000; 86:818-826.
22. Willers J, Urosevic M, Laine E, Geertsen R, Kundig T, Burg G, Dummer R. Decreased intraindividual HLA class I expression is due to reduced transcription in advanced melanoma and does not correlate with HLA-G expression. J Invest Dermatol 2001; 117(6):1498.
23. Becker JC, Brabletz T, Czerny C, Termeer C, Brocker EB. Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. Int J Immunol 1993; 5(12):1501-1508.
24. Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8 + T cells. Cell 1992; 71:1205-1214.
25. Berd D, Herlyn M, Koprowski H, Mastrangelo MJ. Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. Cancer Res 1989; 49:6840-6844.
26. Fetsch PA, Steinberg SM, Riker AI, Marincola FM, Abati A. Melanoma antigen expression in serial fine-needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials: a preliminary look. Cancer 2001; 93(6):409-414.
27. Hofbauer GFL, Geertsen R, Laine E, Burg G, Dummer R. Impact of interferons on the expression of melanoma-associated antigens in melanoma short-term cell cultures. Melanoma Res 2001; 11: 213-218.
28. Mendez R, Serrano A, Jager E, Maleno I, Ruiz-Cabello F, Knuth A, Garrido F. Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens 2001; 57:508-519.